Using genetics to improve asthma treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates how well patients with moderate to severe asthma respond to two approved biologic therapies, dupilumab and benralizumab, by analyzing genomic and biological data from their biosamples. Participants will undergo a series of assessments to characterize their responses to these treatments, which will help identify mechanisms underlying severe asthma. The study aims to enhance personalized treatment strategies by providing insights into which patients are likely to benefit from specific therapies. It follows standard care procedures and includes longitudinal assessments to track individual responses over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Stated willingness to comply with all study procedures and availability for the duration of the study.
* Stable asthma medications: No change in asthma medications for the past 2 months:

  1. Use of medium or high dose inhaled corticosteroids (ICS) AND
  2. Use of an additional asthma controller medication.
* Baseline poor or uncontrolled asthma.
* Evidence of asthma demonstrated by either bronchodilator reversibility (either at screening or by historical evidence) or methacholine responsiveness (by historical evidence).
* Agreement to adhere to Lifestyle Considerations throughout study duration.

Exclusion Criteria:

* Current participation in an interventional trial (e.g. drugs, diets, etc.).
* Currently on an asthma biologic or having been on biologic within 3 months of screening.
* Enrollment in a clinical trial where the study medication was administered within the past 60 days or within 5 half-lives (whichever is greater).
* Physician diagnosis of other chronic pulmonary disorders associated with asthma-like symptoms, including, but not limited to, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways.
* Receiving one or more immune-modulating therapies for diseases other than asthma. This includes biologics that are also approved for asthma.
* Receiving methotrexate, mycophenolate (CellCept®), or azathioprine (Imuran®).
* Receiving aero allergen immunotherapy and not on at least 3 months of maintenance allergen immunotherapy.
* Underwent a bronchial thermoplasty within the last two years.
* Born before 30 weeks of gestation.
* Uncontrolled hypertension, defined as systolic blood pressure \> 160 mm/Hg or diastolic blood pressure \> 100 mm/Hg.
* History of malignancy except non-melanoma skin cancer within the last five years.
* History of smoking:

  1. If \<45 years old: Smoked for ≥5 pack-years\*
  2. If ≥45 years old: Smoked ≥ 10 pack years.
* Active use of any inhalant \>1 time per month in the past year.
* Substance abuse within the last year.
* Unwillingness to practice medically acceptable birth control or complete abstinence during the study, current pregnancy, or lactation.
* Requirement for daily systemic corticosteroids at the time of screening.
* Respiratory infection within 1 month of screening.
* Intubation for asthma in the last 12 months.
* Any clinically significant abnormal findings in the history, physical examination, vital signs, electrocardiogram, hematology or clinical chemistry during run-in period, which in the opinion of the site investigator, may put the participant at risk because of his/her participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
* BMI \> 38.
* Allergic to any of the drugs, biologics or chemicals used in this study.

Where it's running

• Mayo Clinic
  Scottsdale, Arizona, United States Recruiting
• University of California, San Diego
  La Jolla, California, United States Recruiting
• Yale University
  New Haven, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Kelan Tantisira, MD — University of California, San Diego
• Study coordinator: Clinical Trial Operations and Data Management Specialist UA-DCC
• Email: bio5-epiphanydcc@arizona.edu
• Phone: 520-626-9552

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pulmonary Neuromodulation for Asthma Relief in Moderate to Severe Asthma

  This trial tests pulmonary neuromodulation using spinal cord stimulation in adults with uncontrolled moderate to severe asthma to see if it can help improve symptoms.

  Recruiting at 2 sites Spiro Medical, Inc. · Denver, Colorado and 2 other locations · NCT07709754

• RC1416 shots for moderate to severe asthma

  This study tests RC1416 versus placebo to see if it helps adults with severe uncontrolled asthma stay out of flare-ups and breathe better.

  Recruiting at 41 sites Phase 2 Nanjing RegeneCore Biotech Co., Ltd. · Anqing, Anhui and 43 other locations · NCT07403487

• CM326 for adults with moderate to severe asthma

  This 52-week, double-blind, placebo-controlled study will test whether CM326 helps adults (ages 18–80) with moderate to severe asthma who are already on medium-to-high dose inhaled corticosteroids and other controller medicines.

  Recruiting Phase 3 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07372287

• Bringing SMART inhaler therapy to community health clinics

  This project will test a program that helps community clinic clinicians start using SMART inhaler treatment for adults with moderate to severe asthma.

  Recruiting at 5 sites Phase 4 Washington University School of Medicine · St Louis, Missouri and 6 other locations · NCT07241117

• Evaluating CM310 for treating moderate to severe asthma

  This study is testing a new drug called CM310 to see if it can help people with moderate to severe asthma breathe better and feel more comfortable.

  Recruiting Phase 2/3 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Beijing, Beijin · NCT05761028

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.